Potential clinically relevant targets could be delA mutations in breast cancer-causing genes (e.g., BRCA2 c.5578delA46 or EP300 c.5099delA47; CinVar database www.ncbi.nlm.nih.gov/clinvar/). Here, EP300 is linked to breast carcinoma.